Employing this approach, we identified the relevant targets of JM25-1 against IBS and found PI3K-AKT and mTOR signaling pathways are likely to be involved in its drug actions, when PI3K activated AKT is recruited to the plasma membrane and phosphorylated and mTOR is positively regulated through the PI3K/AKT pathway [43]. Here, MTOR is linked to irritable bowel syndrome.